Related Experiment Video
Updated: Jan 17, 2026

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
7-Ketodeoxycholic Acid Promotes Colonic Mucosal Healing by Inducing Calcium Release from Endoplasmic Reticulum via
Jing Zhang1, Feng Jiang2, Wenxin Xia3
1Department of Pharmacognosy, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, P. R. China.
Abstract:
Defective healing of injured mucosa is a hallmark of many pathological conditions, such as ulcerative colitis (UC). Wound healing is a pivotal process that is essential for the reconstruction of epithelial homeostasis following damage to mucous membrane. However, the endogenous metabolites capable of expediting intestinal mucosal healing remain largely undefined. The aim of this study is to identify a pro-repair metabolite to accelerate colonic wound healing. The investigation reveals that the serum levels of 7-ketodeoxycholic acid (7-KDCA), deoxycholic acid (DCA), and lithocholic acid (LCA) are depleted in patients with UC and colitic mice relative to controls. Among the three bile acids, 7-KDCA exhibits the most conspicuous, which is correlated with disease severity. 7-KDCA treatment exerts the strongest promotion of mucosal healing in mice with dextran sulfate sodium-induced mucosal damage or biopsy-induced colonic wounding injury. Mechanistically, 7-KDCA functions by driving intestinal epithelial cell migration through induction of calcium release from the endoplasmic reticulum via targeting the TGR5-IP3R axis. Amidst the array of endogenous metabolites potentially active in progression of UC, 7-KDCA stands out as the preeminent facilitator in the healing of colonic mucosa. This finding may hold clinical significance for treating mucosal defect-related diseases, including UC.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

